Related Experiment Video
Updated: May 14, 2025
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Effectiveness and Toxicity of High-Dose Colistin Treatment in Patients with Multidrug-Resistant Gram-Negative
Daniela Carrasco1, Daniel Muñoz-Pichuante1, Felipe Olivares2
1Instituto de Farmacia, Facultad de Ciencias, Universidad Austral de Chile, Valdivia, Chile.
Abstract:
Hospital-acquired infections by multidrug-resistant Gram-negative bacteria (MDRGN) have become a global public health problem. Colistin is considered one of the last therapeutic options due to its limited clinical effectiveness and high rate of adverse effects. Unfortunately, its use has increase in recent years given the increase of MDRGN-associated infections and narrow therapeutic alternatives. With the aim of improving effectiveness using pharmacokinetic/pharmacodynamic knowledge, higher doses of colistin have been used in recent years but with few reported outcomes.
Methods:
A retrospective cohort analysis was performed in patients with MDRGN infections treated with high-dose colistin with the aim of evaluating clinical improvement as primary outcome and the incidence of acute kidney injury (AKI) and other adverse events as secondary outcomes.
Results:
Fifty-five courses of colistin treatment were identified in 50 patients, with 45% applied on intensive care unit. Clinical improvement was achieved in 35 (63.6%) treatments, while extrapulmonary infections were significantly associated with a higher clinical failure rate (OR 10; 95%CI: 1.18-84.5). By multivariate analysis, only the failure to control the infection source influenced significantly for mortality of patients (aOR= 19.6; IC95 3.0-126, p= 0.002). AKI was observed in 30 treatments (54.5%) and was only significantly associated with the use of a loading doses (OR= 6.0, 95%CI: 1.61-22.3). Eosinophilia was frequent (35.7%) and, besides, two respiratory depression events were observed.
Conclusion:
High doses of colistin could be associated with a favorable clinical improvement in patients with MDRGN infections but has a limited effectiveness in extra-pulmonary infections, especially when a source-control procedure is not performed. AKI is frequently observed and limits its use, while eosinophilia and respiratory depression should be considered also as part of safety monitoring. Prescription of this drug should be judiciously analyzed weighing benefits-to-risk ratio.
Insights
High-dose colistin showed clinical improvement for multidrug-resistant Gram-negative bacterial infections. However, effectiveness was limited in extrapulmonary infections, and acute kidney injury was common, necessitating careful benefit-risk assessment.
Area of Science:
- Infectious Diseases
- Pharmacology
- Nephrology
Background:
- Hospital-acquired infections by multidrug-resistant Gram-negative bacteria (MDRGN) pose a global health challenge.
- Colistin, a last-resort antibiotic, faces limitations in effectiveness and adverse effects.
- Increasing MDRGN infections and limited alternatives have led to higher colistin doses.
Purpose of the Study:
- To evaluate the clinical effectiveness of high-dose colistin in MDRGN infections.
- To assess the incidence of acute kidney injury (AKI) and other adverse events.
- To identify factors influencing clinical outcomes and mortality.
Main Methods:
- Retrospective cohort analysis of patients with MDRGN infections treated with high-dose colistin.
- Primary outcome: clinical improvement.
- Secondary outcomes: incidence of AKI, other adverse events, and mortality.
Main Results:
- Clinical improvement was observed in 63.6% of treatments.
- Extrapulmonary infections were linked to higher clinical failure rates (OR 10).
- Acute kidney injury (AKI) occurred in 54.5% of treatments, associated with loading doses (OR 6.0).
- Failure to control infection source significantly influenced mortality (aOR 19.6).
- Eosinophilia (35.7%) and respiratory depression were noted adverse events.
Conclusions:
- High-dose colistin may improve clinical outcomes in MDRGN infections but is less effective for extrapulmonary sites, especially without source control.
- AKI is a frequent complication, limiting colistin use.
- Eosinophilia and respiratory depression require safety monitoring; judicious use is advised.
More Related Videos
06:19Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
Published on: October 11, 2024
08:19Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
Published on: July 7, 2020
